Asset Details
Do you wish to reserve the book?
Field Evaluation of a Novel Combined Vaccine Against Porcine Circovirus Types 2a/d, Mycoplasma hyopneumoniae and Mycoplasma hyorhinis With an Emphasis on Growth Performance
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Field Evaluation of a Novel Combined Vaccine Against Porcine Circovirus Types 2a/d, Mycoplasma hyopneumoniae and Mycoplasma hyorhinis With an Emphasis on Growth Performance
Do you wish to request the book?
Field Evaluation of a Novel Combined Vaccine Against Porcine Circovirus Types 2a/d, Mycoplasma hyopneumoniae and Mycoplasma hyorhinis With an Emphasis on Growth Performance
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Field Evaluation of a Novel Combined Vaccine Against Porcine Circovirus Types 2a/d, Mycoplasma hyopneumoniae and Mycoplasma hyorhinis With an Emphasis on Growth Performance
2026
Overview
Background A field efficacy trial was conducted on three farms to evaluate a novel combined vaccine containing porcine circovirus types 2a/d (PCV2a/d), Mycoplasma hyopneumoniae, and M. hyorhinis. Methods Three farms with a history of subclinical PCV2 infection, enzootic pneumonia, and polyserositis were enrolled. Each farm included 40 piglets (18 days old), which were randomly allocated to vaccinated or unvaccinated groups. Pigs in the vaccinated group received a single 2‐mL intramuscular dose of the combined vaccine at 21 days of age, while unvaccinated pigs received phosphate‐buffered saline. Results Vaccination significantly improved (p < 0.05) body weight and average daily weight gain on all three farms compared with unvaccinated pigs. Vaccinated pigs mounted protective humoral and cellular immune responses against PCV2, M. hyopneumoniae, and M. hyorhinis. Furthermore, vaccination reduced viral and mycoplasmal loads in serum, laryngeal, and nasal samples and decreased the severity of associated lesions. Conclusions The combined vaccine demonstrated strong efficacy under field conditions, providing protection against subclinical PCV2 infection, enzootic pneumonia caused by M. hyopneumoniae, and polyserositis caused by M. hyorhinis. These findings support its potential as an effective intervention for improving both health and productivity in swine herds. A field trial on three commercial farms evaluated a combined vaccine targeting PCV2a/d, Mycoplasma hyopneumoniae, and Mycoplasma hyorhinis. Vaccinated pigs showed improved average daily weight gain, stronger immune responses against these pathogens, and significantly reduced viral and mycoplasmal loads and lesion severity, supporting its efficacy under field infection conditions.
Publisher
John Wiley & Sons, Inc,Wiley
Subject
/ Animals
/ Bacterial Vaccines - administration & dosage
/ Bacterial Vaccines - immunology
/ Circoviridae Infections - immunology
/ Circoviridae Infections - prevention & control
/ Circoviridae Infections - veterinary
/ Circoviridae Infections - virology
/ Farms
/ Hogs
/ Immune response (cell-mediated)
/ Mycoplasma hyopneumoniae - immunology
/ Mycoplasma hyorhinis - immunology
/ Mycoplasma Infections - prevention & control
/ Mycoplasma Infections - veterinary
/ Pneumonia of Swine, Mycoplasmal - prevention & control
/ porcine circovirus‐associated diseases
/ Swine - growth & development
/ Swine Diseases - microbiology
/ Swine Diseases - prevention & control
/ vaccine
/ Vaccines
/ Vaccines, Combined - immunology
/ Viral Vaccines - administration & dosage
/ Weaning
